# ICON PLC

Summary updated: 2026-10-02T12:42:50.453995Z
Canonical: https://finbar.com/research/companies/icon-plc

## Overview

ICON plc is a global contract research organization (CRO) serving pharmaceutical, biotechnology, medical-device, government and public-health organizations. Its services span clinical development—from early-stage studies through Phase I–IV trials—to post-approval research, commercialization, market access consulting and healthcare technology. [1](https://app.finbar.com/go?id=P153819551)[2](https://app.finbar.com/go?id=P153819552) The company’s stated mission is to improve patients’ lives by accelerating the development of customers’ drugs and devices through innovative solutions. [3](https://app.finbar.com/go?id=P153819618)

Founded in Dublin in 1990, ICON operates internationally; as of September 30, 2025, it reported approximately 39,800 employees, 106 locations in 55 countries, and service-delivery capability in 93 countries. [4](https://www.iconplc.com/about)[5](https://www.iconplc.com/news-events/mediakit/facts-and-figures) For the year ended December 31, 2025, revenue was approximately $8.251 billion. [6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)
[1](https://app.finbar.com/go?id=P153819551)[2](https://app.finbar.com/go?id=P153819552)[3](https://app.finbar.com/go?id=P153819618)[4](https://www.iconplc.com/about)[5](https://www.iconplc.com/news-events/mediakit/facts-and-figures)[6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)[4](https://www.iconplc.com/about)[5](https://www.iconplc.com/news-events/mediakit/facts-and-figures)[6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)

## Products & services

ICON provides clinical development services spanning Phases I–IV, peri- and post-approval studies, trial design and execution, data solutions, consulting, contract staffing and commercialization support. Its laboratory services include central, bioanalytical, biomarker, vaccine, GMP and specialty testing; work can be delivered as full-service programs, strategic partnerships, functional service provision or stand-alone services. [7](https://app.finbar.com/go?id=P153819454)[8](https://app.finbar.com/go?id=P153819498)[9](https://app.finbar.com/go?id=P153819500)[10](https://www.iconplc.com/solutions/laboratories/global-central-laboratories)

Named technology offerings support different stages of trial operations. ICON Digital Platform includes eConsent, electronic clinical outcome assessments (eCOA), eSource, televisits and connected-device data capture. FIRECREST provides site-facing tools for communications, training, document exchange, pre-screening, eConsent and safety-letter workflows, while HORIZON tracks site-activation milestones and offers dashboards, predictive analytics and workflow automation. Other tools described by ICON include One Search for AI/ML-assisted site selection, SmartDraft for contract drafting, Clinical Data Studio for combining data sources, Risk-Based Monitoring for data-led monitoring prioritization, and Flex Advantage for randomization and trial-supply management. [11](https://app.finbar.com/go?id=P153819805)[12](https://app.finbar.com/go?id=P153819812)[13](https://app.finbar.com/go?id=P153819817)[14](https://app.finbar.com/go?id=P153819820)[15](https://app.finbar.com/go?id=P153819821)[16](https://www.iconplc.com/solutions/technologies/icon-digital-platform)[17](https://www.iconplc.com/solutions/technologies/firecrest)[18](https://www.iconplc.com/solutions/technologies/horizon)

Accellacare offers site and patient services, including site start-up, recruitment and retention support, site resourcing, and in-home trial visits. ICON’s filing describes its owned or embedded site network and in-home services; company pages also describe central-lab sample tracking and kit management through LabView360. ICON reports one reportable segment and does not disclose revenue or performance percentages by individual product or service. [19](https://app.finbar.com/go?id=P153819514)[20](https://app.finbar.com/go?id=P153819515)[21](https://app.finbar.com/go?id=P153819517)[22](https://app.finbar.com/go?id=P153822118)[23](https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions)[24](https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services)[25](https://www.iconplc.com/solutions/technologies/labview360)
[7](https://app.finbar.com/go?id=P153819454)[8](https://app.finbar.com/go?id=P153819498)[9](https://app.finbar.com/go?id=P153819500)[10](https://www.iconplc.com/solutions/laboratories/global-central-laboratories)[11](https://app.finbar.com/go?id=P153819805)[12](https://app.finbar.com/go?id=P153819812)[13](https://app.finbar.com/go?id=P153819817)[14](https://app.finbar.com/go?id=P153819820)[15](https://app.finbar.com/go?id=P153819821)[16](https://www.iconplc.com/solutions/technologies/icon-digital-platform)[17](https://www.iconplc.com/solutions/technologies/firecrest)[18](https://www.iconplc.com/solutions/technologies/horizon)[19](https://app.finbar.com/go?id=P153819514)[20](https://app.finbar.com/go?id=P153819515)[21](https://app.finbar.com/go?id=P153819517)[22](https://app.finbar.com/go?id=P153822118)[23](https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions)[24](https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services)[25](https://www.iconplc.com/solutions/technologies/labview360)[10](https://www.iconplc.com/solutions/laboratories/global-central-laboratories)[16](https://www.iconplc.com/solutions/technologies/icon-digital-platform)[17](https://www.iconplc.com/solutions/technologies/firecrest)[18](https://www.iconplc.com/solutions/technologies/horizon)[23](https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions)[24](https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services)[25](https://www.iconplc.com/solutions/technologies/labview360)

## Geographic presence

In FY2025, ICON plc reported revenue of 30.6% from the United States, 57.9% from Europe, and 11.5% from the Rest of the World. Its geographic revenue discussion separately reported $3,183.6 million in Ireland, $1,590.9 million in the rest of Europe, $2,524.9 million in the United States, and $951.9 million in the Rest of the World/Other. ICON cautions that Ireland revenue primarily reflects its global contracting model, rather than necessarily indicating where customers are located or services are performed. [26](https://app.finbar.com/go?id=P153819901)[27](https://app.finbar.com/go?id=P153819902)[28](https://app.finbar.com/go?id=P153819903)

At December 31, 2025, ICON had approximately 40,100 employees at 97 locations in 55 countries; the filing does not give an employee breakdown by region. [29](https://app.finbar.com/go?id=P153819883) Its corporate headquarters are in Leopardstown, Dublin, Ireland. [30](https://www.iconplc.com/contact)
[26](https://app.finbar.com/go?id=P153819901)[27](https://app.finbar.com/go?id=P153819902)[28](https://app.finbar.com/go?id=P153819903)[29](https://app.finbar.com/go?id=P153819883)[30](https://www.iconplc.com/contact)

## Business segments

ICON reports one financial segment: the global provision of outsourced development services to pharmaceutical, biotechnology and medical-device companies. This segment represents 100% of reported revenue; FY2025 revenue was $8.251 billion. ICON does not report revenue contributions separately for its service lines. [22](https://app.finbar.com/go?id=P153822118)[31](https://app.finbar.com/go?id=P153822120)[6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)

Its service offerings include early-phase development and clinical pharmacology; clinical-trial operations and data science; site and patient support, including recruitment and retention; laboratory testing; and consulting on development, regulatory strategy and commercial positioning. These are service categories, not separately reported financial segments, so no revenue percentages can be assigned to them from ICON’s disclosures. [32](https://www.iconplc.com/solutions/early-clinical)[33](https://www.iconplc.com/solutions/clinical-scientific-operations)[34](https://www.iconplc.com/solutions/site-and-patient-solutions)[35](https://www.iconplc.com/solutions/laboratories)[36](https://www.iconplc.com/solutions/consulting)[37](https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting)
[22](https://app.finbar.com/go?id=P153822118)[31](https://app.finbar.com/go?id=P153822120)[6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)[32](https://www.iconplc.com/solutions/early-clinical)[33](https://www.iconplc.com/solutions/clinical-scientific-operations)[34](https://www.iconplc.com/solutions/site-and-patient-solutions)[35](https://www.iconplc.com/solutions/laboratories)[36](https://www.iconplc.com/solutions/consulting)[37](https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting)[6](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)[32](https://www.iconplc.com/solutions/early-clinical)[33](https://www.iconplc.com/solutions/clinical-scientific-operations)[34](https://www.iconplc.com/solutions/site-and-patient-solutions)[35](https://www.iconplc.com/solutions/laboratories)[36](https://www.iconplc.com/solutions/consulting)[37](https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting)

## Company history

ICON plc was founded in Dublin in 1990 by Dr. John Climax and Dr. Ronan Lambe, initially with a five-person team. It completed its initial public offering on May 15, 1998. [38](https://app.finbar.com/go?id=P153819452)[39](https://www.iconplc.com/about/company-history)[40](https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3)[41](https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4)

During the 2000s and 2010s, ICON expanded its geographic reach and broadened its services through acquisitions, including UK regulatory-affairs consultancy YRCR and US clinical-trial laboratory UCT in 2000, clinical-development company Aptiv Solutions in 2014, and health-outcomes research firm Mapi Group in 2017. [42](https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71)[43](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory)[44](https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions)[45](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group)

In 2021, ICON completed its acquisition of PRA Health Sciences, creating a larger clinical research organization under the ICON name. It acquired KCR in 2024. In 2025, Barry Balfe succeeded Steve Cutler as CEO, marking a leadership transition after Cutler had led the company since 2017. [46](https://app.finbar.com/go?id=P153819471)[47](https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation)[48](https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm)[49](https://app.finbar.com/go?id=P153820209)[50](https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition)
[38](https://app.finbar.com/go?id=P153819452)[39](https://www.iconplc.com/about/company-history)[40](https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3)[41](https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4)[42](https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71)[43](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory)[44](https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions)[45](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group)[46](https://app.finbar.com/go?id=P153819471)[47](https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation)[48](https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm)[49](https://app.finbar.com/go?id=P153820209)[50](https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition)[39](https://www.iconplc.com/about/company-history)[40](https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3)[41](https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4)[42](https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71)[43](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory)[44](https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions)[45](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group)[47](https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation)[48](https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm)[50](https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition)

## Sources

1. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819551)
2. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819552)
3. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819618)
4. [www.iconplc.com](https://www.iconplc.com/about)
5. [www.iconplc.com](https://www.iconplc.com/news-events/mediakit/facts-and-figures)
6. [investor.iconplc.com](https://investor.iconplc.com/news-releases/news-release-details/icon-reports-fourth-quarter-and-full-year-2025-results-and)
7. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819454)
8. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819498)
9. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819500)
10. [www.iconplc.com](https://www.iconplc.com/solutions/laboratories/global-central-laboratories)
11. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819805)
12. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819812)
13. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819817)
14. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819820)
15. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819821)
16. [www.iconplc.com](https://www.iconplc.com/solutions/technologies/icon-digital-platform)
17. [www.iconplc.com](https://www.iconplc.com/solutions/technologies/firecrest)
18. [www.iconplc.com](https://www.iconplc.com/solutions/technologies/horizon)
19. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819514)
20. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819515)
21. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819517)
22. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153822118)
23. [www.iconplc.com](https://www.iconplc.com/solutions/site-and-patient-solutions/sites/clinical-site-solutions)
24. [www.iconplc.com](https://www.iconplc.com/solutions/decentralised-clinical-trials/In-home-clinical-services)
25. [www.iconplc.com](https://www.iconplc.com/solutions/technologies/labview360)
26. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819901)
27. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819902)
28. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819903)
29. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819883)
30. [www.iconplc.com](https://www.iconplc.com/contact)
31. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153822120)
32. [www.iconplc.com](https://www.iconplc.com/solutions/early-clinical)
33. [www.iconplc.com](https://www.iconplc.com/solutions/clinical-scientific-operations)
34. [www.iconplc.com](https://www.iconplc.com/solutions/site-and-patient-solutions)
35. [www.iconplc.com](https://www.iconplc.com/solutions/laboratories)
36. [www.iconplc.com](https://www.iconplc.com/solutions/consulting)
37. [www.iconplc.com](https://www.iconplc.com/solutions/consulting/commercial-positioning-consulting)
38. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819452)
39. [www.iconplc.com](https://www.iconplc.com/about/company-history)
40. [investor.iconplc.com](https://investor.iconplc.com/static-files/5cd01093-e5f4-413e-812f-9976043491a3)
41. [investor.iconplc.com](https://investor.iconplc.com/static-files/f95ccb9b-5c86-4e2a-8e69-2f40bd3cc5b4)
42. [investor.iconplc.com](https://investor.iconplc.com/static-files/d672d285-266a-425b-860a-f51e146fba71)
43. [investor.iconplc.com](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-us-central-clinical-laboratory)
44. [investor.iconplc.com](https://investor.iconplc.com/news-releases/news-release-details/icon-completes-acquisition-aptiv-solutions)
45. [investor.iconplc.com](https://investor.iconplc.com/news-releases/news-release-details/icon-acquires-mapi-group)
46. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153819471)
47. [www.iconplc.com](https://www.iconplc.com/news-events/press-releases/world-leading-healthcare-intelligence-and-clinical-research-organisation)
48. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1060955/000106095524000090/iclr-20240930.htm)
49. [ICON PLC — Full financial report (2025 Y)](https://app.finbar.com/go?id=P153820209)
50. [www.iconplc.com](https://www.iconplc.com/news-events/press-releases/icon-announces-ceo-transition)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.